Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

Live Evaluations

Preventing Pruritus in Atopic Dermatitis: Are Biologics an Answer?


Preventing Pruritus in Atopic Dermatitis: Are Biologics an Answer 

This activity is supported by educational grants from Sanofi and Regeneron Pharmaceuticals and Galderma.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Discuss the burden of itch on quality of life

  • Describe the pathophysiology of itch in atopic dermatitis

  • Analyze safety and efficacy data for current and emerging biologic therapies that target itch pathways in atopic dermatitis

  • Demonstrate strategies to individualize care to manage itch with biologic therapies in atopic dermatitis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Susan Taylor, MD

Incoming President-elect, American Academy of Dermatology
Bernett L. Johnson Endowed Professor in Dermatology
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Joshua Zeichner, MD

Director of Cosmetic and Clinical Research 
Icahn School of Medicine at Mount Sinai 
New York, NY

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Susan C. Taylor, MD

Advisory Board: AbbVie, Avita Medical, Beiersdorf, Biorez (past), Eli Lilly, EPI Health, Evolus, Galderma, Hugel America, Incyte, Johnson & Johnson, L'Oreal USA, Medscape, Pfizer, Scientis US, UCB, Vichy Laboratoires Grant/Research Support: Allergan Aesthetics, Concert Pharmaceuticals/Sun Pharma, Croma Pharma GmbH, Eli Lilly, Pfizer Consultant: Arcutis, Armis Scientific, Beiersdorf, Bristol Myers Squibb, Cara Therapeutics, Dior, GloGetter, Piction Health, Sanofi Speakers’ Bureau or Honoraria: Beiersdorf, Medscape, MJH Lifesciences Royalty: McGraw Hill Publishing Ownership Interest (privately held): Armis Scientific, GloGetter, Piction Health Other Financial Benefit: Mercer Strategies LLC

Joshua Zeichner, MD

Consultant: Abbvie, Allergan, Arcutis, Beiersdorf, Dermavant, Galderma, Incyte, Kenvue, L'Oreal, Pfizer, Procter & Gamble, Sun, Unilever, UCB

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved